Literature DB >> 16989838

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.

Amanda J Hooper1, A David Marais, Donald M Tanyanyiwa, John R Burnett.   

Abstract

OBJECTIVE: Missense mutations in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) can cause familial hypercholesterolemia. However, two nonsense variants of PCSK9, Y142X and C679X, found in approximately 2% of black American subjects, are associated with a 28% reduction in mean low density lipoprotein (LDL)-cholesterol. We sought to determine the frequency and effect of these nonsense variants in an African population. METHODS AND
RESULTS: PCSK9 genotypes were determined in 653 black African women attending two antenatal clinics in Zimbabwe. C679X occurred in 3.7% of subjects and was associated with a 27% reduction in LDL-cholesterol (1.6+/-0.3 mmol/L versus 2.2+/-0.7 mmol/L in non-carriers). We did not observe the Y142X variant.
CONCLUSIONS: Our results show that the PCSK9 C679X variant has a marked cholesterol-lowering effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989838     DOI: 10.1016/j.atherosclerosis.2006.08.039

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  97 in total

Review 1.  Protective alleles and modifier variants in human health and disease.

Authors:  Andrew R Harper; Shalini Nayee; Eric J Topol
Journal:  Nat Rev Genet       Date:  2015-10-27       Impact factor: 53.242

Review 2.  Genetics of extreme human longevity to guide drug discovery for healthy ageing.

Authors:  Zhengdong D Zhang; Sofiya Milman; Jhih-Rong Lin; Shayne Wierbowski; Haiyuan Yu; Nir Barzilai; Vera Gorbunova; Warren C Ladiges; Laura J Niedernhofer; Yousin Suh; Paul D Robbins; Jan Vijg
Journal:  Nat Metab       Date:  2020-07-27

3.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-07       Impact factor: 5.922

4.  Human genetics as a foundation for innovative drug development.

Authors:  Alexander Kamb; Sean Harper; Kari Stefansson
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

Review 5.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

6.  Genetic Determinants of Dyslipidemia in African-Based Populations: A Systematic Review.

Authors:  Jean Jacques Noubiap; Edith Pascale M Mato; Magellan Guewo-Fokeng; Arnaud D Kaze; Houssam Boulenouar; Ambroise Wonkam
Journal:  OMICS       Date:  2018-12

7.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

8.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Authors:  Kevin Fitzgerald; Maria Frank-Kamenetsky; Svetlana Shulga-Morskaya; Abigail Liebow; Brian R Bettencourt; Jessica E Sutherland; Renta M Hutabarat; Valerie A Clausen; Verena Karsten; Jeffrey Cehelsky; Saraswathy V Nochur; Victor Kotelianski; Jay Horton; Timothy Mant; Joseph Chiesa; James Ritter; Malathy Munisamy; Akshay K Vaishnaw; Jared A Gollob; Amy Simon
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

9.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02

10.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.